medigraphic.com

2005, Número 1

<< Anterior Siguiente >>

Med Sur 2005; 12 (1)


Nuevas modalidades de imagen: PET-CT

Vega-González IF, Graef SA, García-Reyna JC, Ornelas AM

Idioma: Español
Referencias bibliográficas: 59
Paginas: 11-25
Archivo PDF: 313.49 Kb.


RESUMEN

Dentro de la nueva tendencia observada en el mundo, de fusionar las imágenes metabólicas realizadas con la tomografía por emisión de positrones (PET), con las imágenes morfológicas, realizadas por la tomografía computarizada (TC), el propósito de esta revisión es aclarar los términos utilizados en esta nueva modalidad de imagen, describir el funcionamiento de este nuevo equipo de apoyo diagnóstico, así como enumerar las indicaciones de estos estudios.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. CONAPO, 2002. Proyecciones de la Población de México, 2000 – 2050, http://busca.ssa.gob.mx/cgi-bin/s.cgi?q=MORTALIDAD.

  2. McCarthy TJ, Schwarz SW, Welch MJ. Nuclear Medicine and PET: an overview. J Chem Ed 1994; 71: 830-836.

  3. Finn RD. The search for consistency in the manufacture of PET radiopharmaceuticals. Ann Nucl MED 1999; 132379-382.

  4. Robert R. Morris, first edition, Book of Society of Nuclear Medicine 1954-2002, 50 years of excellence. 2004. Special Edition.

  5. McCarthy TJ, Welch MJ. The state of positron emitting radionuclide production in 1997. Sem Nucl Med 28: 235-246.

  6. Murray IPC. Nuclear Medicine in Clinical Diagnosis and treatment, text book. Sidney Australia, 1994; 8: 1279-1298.

  7. Freedman G. Tomographic imaging in nuclear medicine. New York: New York Society of nuclear medicine, ed. 1973: 151-153.

  8. Kinahan PE, Townsend DW, Beyer T et al. PET Attenuation correction for a combined 3D PET/CT scanner. Med Phys 1998; 25: 2046-2053.

  9. Pisani P, Guzzardi R, Bellina CR, Sorace O. User-friendly image processing software tools: general purpose features and application to the correlation of PET-CT brain images. Med Prog Technol 1991; 17(3-4): 205-9.

  10. Townsend DW, Cherry SR. Combining anatomic and function, the path of the true image fusion. Eur Radiol 2001; 11: 1968-1974.

  11. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189(3): 847-50.

  12. Tse N, Hoh C, Hawkins R et al. The application of PET imaging with FDG to the evaluation of breast disease. Ann Sur 1992; 216: 27-34.

  13. Gustav K, Von Schulthess. PET, PET/CT and SPECT/CT. Clinical Molecular Anatomic Imaging. Philadelphia: 2003: 141-144.

  14. Davson P, Cosgrove DO, Grainger RG. Text Book of contrast media. Oxford: Isis Medical Media Ltd. eds., 1999.

  15. Groves AM, Bird N, Tabor I, Cheow HK, Balan KK. 16-Detector multislice CT-skeletal scintigraphy image co-registration. Nucl Med Commun 2004; 25(11): 1151-5.

  16. Wahl RL, Buchanan JW. Principles and Practice of Positron Emission Tomography. Philadelphia. Chapter 5.2; 2002: 111-136.

  17. Oehr P, Jbiersack HP, Coleman RE. PET and PET-CT in Oncology. New York 2004.

  18. Cowan RJ. Conventional Radionuclide Brain Imaging in the Era of Transmission and Emission Tomography. Sem Nucl Med 1986; 16: 63-73.

  19. Cohade C, Wahl RL. Applications of Positron Emission Tomography/Computed Tomography Image Fusion in Clinical Positron Emission Tomography-Clinical Use, Interpretation Methods, Diagnostic Improvements. Sem Nucl Med 2003; 3: 228-237.

  20. Bacharach SL. The new-generation positron emission tomography computed tomography scanners: Implications for cardiac imaging. J Nucl Cardiol 2004; 11: 388-92.

  21. 21.Xu SW, Zhang XL, Zeng JH, Wang JY, Li TR, Qian GN, Gao RG. Clinical application of 16-slice spiral CT coronary Angiography. Di Yi Jun Yi Da Xue Xue Bao 2005; 25(2): 218-22.

  22. Charron M et al. Image analysis in patients whit cancer studied with a combinated PET and CT scanner. Clin Nucl Med 25: 905-910.

  23. Touboul E, Deniaud-Alexandre E, Moureau-Zabotto L, Lerouge D. The impact of integrating images of positron emission tomography with computed tomography simulation on radiation therapy planning Cancer Radiother. 2004; 8(Suppl 1): S29-35.

  24. Bockisch A, Beyer T, Antoch G, Freudenberg LS et al. Positron emission tomography/computed tomography—imaging protocols, artifacts, and pitfalls. Mol Imaging Biol 2004; 6(4): 188-99.

  25. Myers R. The application of PET-MRI image registration in the brain. BJR 2002; 75: S31-S35.

  26. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25: 1255-60.

  27. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285: 914-24.

  28. Reske S, Grillenberger KG, Glatting G. Overexpression of glucose transporter 1 and increased F-18 FDG uptake in pancreatic carcinoma. J Nucl Med 1997; 38: 1344-1348.

  29. Inokuma T, Tamaki N, Torizuka T. Evaluation of pancreatic tumor with PET and F18- FDG: Comparison with CT and US. Radiology 1995; 195: 345-352.

  30. van Westreenen HL, Heeren PA, van Dullemen HM, van der Jagt EJ, Jager PL, Groen H, Plukker JT. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg 2005; 9: 54-61.

  31. Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, Tage-Jensen U, Dahlerup JF. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Ugeskr Laeger 2000; 162: 782-5.

  32. Hustinx R. PET imaging in assessing gastrointestinal tumors. Radiol Clin North Am 2004; 42: 1123-39.

  33. Larson SM, Schoder H, Yeung H. Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer. Cancer J 2004; 10: 243-50.

  34. Sironi S, Messa C, Mangili G, Zangheri B, Aletti G et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004; 233: 433-40.

  35. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34: 274-92.

  36. De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19: 3740-4.

  37. Muller-Mattheis V, Reinhardt M, Gerharz CD, Furst G. Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors. Urologe A 1998; 37: 609-20.

  38. Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 200; 59: 913-8.

  39. Matthies A, Ezziddin S, Ulrich EM, Palmedo H, Biersack HJ, Bender H, Guhlke S. Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging 2004; 31: 797.

  40. Weng LJ, Schoder H. Melanoma metastasis to the testis demonstrated with F Schmidt GP, Baur-Melnyk A, Tiling R, Hahn K, Reiser MF,

  41. Schoenberg SO. DG PET/CT. Clin Nucl Med 2004; 29: 811-2.

  42. Comparison of high resolution whole-body MRI using parallel imaging and PET-CT. First experiences with a 32-channel MRI system. Radiologe 2004; 44: 889-98.

  43. Steinert HC. PET/CT in lymphoma patients. Radiologe 2004; 44: 1060-7.

  44. Wiedmann E, Baican B, Hertel A, Baum RP, Chow KU. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin’s disease. Leuk Lymphoma 1999; 34: 545-51.

  45. Martí JM, Maldonado A. SPECT cerebral: fundamentos e interpretación. Rev Neurol 1994; 22: S9-S18.

  46. Cowan RJ. Conventional Radionuclide Brain Imaging in the Era of Transmission and Emission Tomography. Sem Nucl Med 1986; 16: 63-73.

  47. Arbizu J, García Velloso MJ. Radiotrazadores en SPECT Cerebral. Rev Neurol 1994; 22: S19-S27.

  48. Lassen NA. On the history of measurement of cerebral blood flow in man by radioactive isotopes. In: Costa DC, Morgan GF, Lassen NA. New Trends in Nuclear Neurology and Psychiatry. (Eds.) John Libbey. London 1993: 3-13.

  49. Miles KA. Brain Perfusion: computed tomography applications. Neuroradiology 2004; 46(Suppl 2): 194-200.

  50. Cohade C, Wahl RL. Applications of Positron Emission Tomography/Computed Tomography Image Fusion in Clinical Positron Emission Tomography-Clinical Use, Interpretation Methods, Diagnostic Improvements. Sem Nucl Med 2003; 3: 228-237.

  51. Steinert HC, Von Schulthess GK. Initial clinical experience using a new integrated in-line PET/CT system. BJR 2002; 75: S36-S38.

  52. 51.Kluetz P, Villemagne VV, Meltzer C, Chander S, Martinelli M, Townset D. The Case for PET/CT. Experience at the University of Pittsburgh. Clin Positron Imaging 2000; 3(4): 174.

  53. Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. BJR 2002; 75: S24-S30.

  54. Cochrane MJ, Lee IS. PET/CT for Tumor Imaging. Radiology Rounds 2004: 2(5).

  55. Barry L. Zaret MD, Second Annual Mario S. Verani, MD, Memorial Lecture . Nuclear cardiology, the next 10 years. J Nucl Cardiol 2004; 11: 393-407.

  56. Ornelas AM. Tomografía por emisión de positrones (PET) en Cardiología nuclear. Boletín de Medicina Nuclear en Cardiología SMMN 2003; 1(2): 3.

  57. Santana BC, García EV. Tomografía por emisión de positrones en Cardiología Emory University Atlanta GA. (En impresión).

  58. Roenlandt JR. Seeing the Heart; the success story of cardiac imaging. European Heart Journal 2000; 21: 1281-1288.

  59. Bacharach SL. The new-generation positron emission tomography computed tomography scanners: Implications for cardiac imaging. J Nucl Cardiol 2004; 11: 388-92.




2020     |     www.medigraphic.com